Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB06268_DB08895_nanopub.RAU2cMzWnMyZL3OBLUP0eUM9_ocPgKs1xk0iXLW_GaJT0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB06268_DB08895 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB06268_DB08895 label "DDI between Sitaxentan and Tofacitinib - Sitaxentan (moderate CYP3A4 inhibitors, strong CYP2C19 inhbitors), when used in combination with tofacitinib, may increase tofaciitinib serum concentration toxicity and adverse effects. It is recommended to adjust therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5 mg daily. [drugbank_resource:DB06268_DB08895]" assertion.
- drugbank_resource:DB06268_DB08895 identifier "drugbank_resource:DB06268_DB08895" assertion.
- drugbank_resource:DB06268_DB08895 title "DDI between Sitaxentan and Tofacitinib - Sitaxentan (moderate CYP3A4 inhibitors, strong CYP2C19 inhbitors), when used in combination with tofacitinib, may increase tofaciitinib serum concentration toxicity and adverse effects. It is recommended to adjust therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5 mg daily." assertion.
- drugbank:DB08895 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB06268_DB08895 assertion.
- drugbank:DB06268 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB06268_DB08895 assertion.